Literature DB >> 19614797

Resveratrol: biologic and therapeutic implications.

Sarfaraz Sadruddin1, Rohit Arora.   

Abstract

Resveratrol (3,4',5 trihydroxystilbene), a naturally-occurring molecule known as a phytoalexin, is synthesized by plants in response to attacks by fungi, bacteria, or other injurious substances; it is also known to possess an array of cardioprotective effects. Recently, studies have shown resveratrol to protect against the metabolic changes associated with hypercaloric diets in mice with induced insulin resistance, hyperglycemia, and dyslipidemia. Despite impressive gains in diagnosis and treatment, cardiovascular disease (CVD) remains a serious clinical problem and threat to public health. The metabolic syndrome, which identifies persons at higher risk for diabetes mellitus and CVD, is approaching a prevalence of nearly 25% of the western world. If the metabolic syndrome can be considered a polar opposite to caloric restriction, then agents that mimic caloric restriction may offer a new therapeutic approach to preventing CVD. The authors discuss the cardioprotective effects of resveratrol and highlight its role in glucose homeostasis and lipid metabolism in mice. Armed with the ability to prevent the deleterious effects of excess caloric intake and prevent detrimental cardiovascular events, resveratrol merits proper clinical investigations for its efficacy in treating metabolic diseases and CVD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19614797     DOI: 10.1111/j.1559-4572.2008.00039.x

Source DB:  PubMed          Journal:  J Cardiometab Syndr        ISSN: 1559-4564


  15 in total

Review 1.  Applied Healthspan engineering.

Authors:  James W Larrick; Andrew Mendelsohn
Journal:  Rejuvenation Res       Date:  2010 Apr-Jun       Impact factor: 4.663

2.  Closer association of mitochondria with lipid droplets in hepatocytes and activation of Kupffer cells in resveratrol-treated senescence-accelerated mice.

Authors:  Motoko Shiozaki; Naoya Hayakawa; Masahiro Shibata; Masato Koike; Yasuo Uchiyama; Takahiro Gotow
Journal:  Histochem Cell Biol       Date:  2011-08-05       Impact factor: 4.304

Review 3.  Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders.

Authors:  Vittorio Calabrese; Carolin Cornelius; Albena T Dinkova-Kostova; Edward J Calabrese; Mark P Mattson
Journal:  Antioxid Redox Signal       Date:  2010-08-28       Impact factor: 8.401

Review 4.  Peanuts as functional food: a review.

Authors:  Shalini S Arya; Akshata R Salve; S Chauhan
Journal:  J Food Sci Technol       Date:  2015-09-19       Impact factor: 2.701

5.  Proteostasis: a new therapeutic paradigm for pulmonary disease.

Authors:  Marion Bouchecareilh; William E Balch
Journal:  Proc Am Thorac Soc       Date:  2011-05

6.  Arvelexin from Brassica rapa suppresses NF-κB-regulated pro-inflammatory gene expression by inhibiting activation of IκB kinase.

Authors:  Ji-Sun Shin; Young-Su Noh; Yong Sup Lee; Young-Wuk Cho; Nam-In Baek; Myung-Sook Choi; Tae-Sook Jeong; Eunkyung Kang; Hae-Gon Chung; Kyung-Tae Lee
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

7.  Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity.

Authors:  Alexandre Dal-Pan; Stéphane Blanc; Fabienne Aujard
Journal:  BMC Physiol       Date:  2010-06-22

8.  Liposomal Antioxidants for Protection against Oxidant-Induced Damage.

Authors:  Zacharias E Suntres
Journal:  J Toxicol       Date:  2011-08-16

9.  Resveratrol stimulates sphingosine-1-phosphate signaling of cathelicidin production.

Authors:  Kyungho Park; Peter M Elias; Melanie Hupe; Andrew W Borkowski; Richard L Gallo; Kyong-Oh Shin; Yong-Moon Lee; Walter M Holleran; Yoshikazu Uchida
Journal:  J Invest Dermatol       Date:  2013-03-14       Impact factor: 8.551

10.  Resveratrol inhibits phenotype modulation by platelet derived growth factor-bb in rat aortic smooth muscle cells.

Authors:  Mi Hee Lee; Byeong-Ju Kwon; Hyok Jin Seo; Kyeong Eun Yoo; Min Sung Kim; Min-Ah Koo; Jong-Chul Park
Journal:  Oxid Med Cell Longev       Date:  2014-03-10       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.